Actavis PLC (ACT.N)

ACT.N on New York Stock Exchange

289.78USD
26 Feb 2015
Change (% chg)

$-0.62 (-0.21%)
Prev Close
$290.40
Open
$290.40
Day's High
$291.70
Day's Low
$286.66
Volume
477,713
Avg. Vol
474,882
52-wk High
$296.73
52-wk Low
$184.94

ACT.N

Chart for ACT.N

About

Actavis PLC, is a global, integrated specialty pharmaceutical company. The Company focused on developing, manufacturing and distributing generic, brand and biosimilar products. The Company produces and markets generic, branded generic, branded and over-the-counter (OTC) pharmaceutical products covering all therapeutic classes.... (more)

Overall

Beta: 0.31
Market Cap(Mil.): $77,154.59
Shares Outstanding(Mil.): 266.25
Dividend: --
Yield (%): --

Financials

  ACT.N Industry Sector
P/E (TTM): -- 38.99 40.21
EPS (TTM): -6.09 -- --
ROI: -4.87 17.01 16.34
ROE: -8.61 17.53 17.27
Search Stocks

Actavis' superbug antibiotic gets U.S. approval

- The U.S. Food and Drug Administration on Wednesday approved the use of Actavis Plc's antibiotic, Avycaz, to battle drug-resistant bacteria known as superbugs.

26 Feb 2015

CORRECTED-(OFFICIAL)-UPDATE 1-Actavis' superbug antibiotic gets U.S. approval (Feb. 25)

Feb 25 - The U.S. Food and Drug Administration on Wednesday approved the use of Actavis Plc's antibiotic, Avycaz, to battle drug-resistant bacteria known as superbugs.

26 Feb 2015

CORRECTED-Actavis' superbug antibiotic gets U.S. approval

Feb 25 - The U.S Food and Drug Administration approved on Wednesday Actavis Plc's antibiotic to treat two infections caused by drug-resistant bacteria, or superbugs.

26 Feb 2015

Actavis' superbug antibiotic gets U.S. approval

- The U.S Food and Drug Administration approved on Wednesday Actavis Plc's antibiotic to treat two infections caused by drug-resistant bacteria, or superbugs.

26 Feb 2015

UPDATE 3-Actavis to take Allergan name, reflecting brand-drug focus

NEW YORK, Feb 18 - Actavis Plc, a generic drugmaker that has been steadily acquiring branded medicines, said it will change its name to Allergan Inc after it completes its planned $66 billion purchase of the Botox maker, signaling its growing focus on patent-protected drugs.

18 Feb 2015

Actavis CEO expects further pharmaceutical industry consolidation

Feb 18 - Actavis PLC Chief Executive Officer Brent Saunders said on Wednesday that the pharmaceutical industry will continue to consolidate because of inefficiencies in research and development and product commercialization.

18 Feb 2015

Actavis CEO says no "transformational" deals for now

Feb 18 - Actavis Plc Chief Executive Officer Brent Saunders said on Wednesday that the company has sidelined large deals that involve moving into new therapeutic areas as it focuses on cutting its debt, but that the drugmaker continues to look at small acquisitions that fit with its current businesses.

18 Feb 2015

Actavis adjusted profit beats estimates

Feb 18 - Drugmaker Actavis Plc posted a better-than-expected adjusted quarterly profit, helped by higher sales of its branded drugs in North America.

18 Feb 2015

EU mergers and takeovers (Feb 10)

BRUSSELS, Feb 10 - The following are mergers under review by the European Commission and a brief guide to the EU merger process:

10 Feb 2015

UPDATE 3-AstraZeneca to buy Actavis lung drugs as earnings fall short

* Q4 core EPS 76 cents vs consensus 82 cents (Adds further CEO comments on deals, Breakingviews link)

05 Feb 2015

Earnings vs. Estimates

Search Stocks